Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| 1 |
Moderna
MRNA
|
$2.75B |
| 2 |
Coupang
CPNG
|
$1.09B |
| 3 |
Trade Desk
TTD
|
$793M |
| 4 |
BioNTech
BNTX
|
$736M |
| 5 |
Bilibili
BILI
|
$639M |
Top Sells
| 1 |
Tesla
TSLA
|
$7.41B |
| 2 |
Alphabet (Google) Class C
GOOG
|
$1.39B |
| 3 |
Meta Platforms (Facebook)
META
|
$880M |
| 4 |
Amazon
AMZN
|
$773M |
| 5 |
NIO
NIO
|
$619M |
Sector Composition
| 1 | Consumer Discretionary | 31.93% |
| 2 | Healthcare | 19.13% |
| 3 | Technology | 17.13% |
| 4 | Communication Services | 14.58% |
| 5 | Financials | 5.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
HEICO
HEI
$44.8B
| $20.8M | 0.01% |
165,121
+8,073
| +5% | +$1.02M |
|
227
BridgeBio Pharma
BBIO
$9.77B
| $19.3M | 0.01% |
312,645
+194,113
| +164% | +$12M |
|
|
NCNA
228
NuCana
NCNA
$5.4M
| $18.3M | 0.01% |
732
+68
| +10% | +$1.7M |
|
229
Align Technology
ALGN
$9.71B
| $15.9M | 0.01% |
29,346
| – | – |
|
230
Masimo
MASI
$7.73B
| $15.6M | 0.01% |
68,098
+36,731
| +117% | +$8.44M |
|
231
Visa
V
$682B
| $15.3M | 0.01% |
72,337
| – | – |
|
232
Cooper Companies
COO
$13.3B
| $13.7M | 0.01% |
142,800
| – | – |
|
233
Invesco Senior Income Trust
VVR
$555M
| $13.4M | 0.01% |
3,195,695
| – | – |
|
234
Ascendis Pharma
ASND
$12.1B
| $13.2M | 0.01% |
102,294
+55,139
| +117% | +$7.11M |
|
|
KDNY
235
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $13.1M | 0.01% |
845,485
+801
| +0.1% | +$12.4K |
|
|
BNFT
236
DELISTED
Benefitfocus, Inc.
BNFT
| $13M | 0.01% |
944,514
-3,098
| -0.3% | -$42.8K |
|
237
Health Catalyst
HCAT
$226M
| $12.3M | 0.01% |
262,830
+140,777
| +115% | +$6.58M |
|
238
Sherwin-Williams
SHW
$91.1B
| $12.3M | 0.01% |
49,893
| – | – |
|
239
Ionis Pharmaceuticals
IONS
$9.48B
| $10.7M | 0.01% |
237,959
+111,741
| +89% | +$5.02M |
|
240
Verisk Analytics
VRSK
$37.5B
| $10.2M | 0.01% |
57,521
| – | – |
|
241
BlackRock Floating Rate Income Trust
BGT
$317M
| $9.81M | 0.01% |
784,230
| – | – |
|
242
HUTCHMED
HCM
$2.55B
| $9.13M | 0.01% |
323,153
+29,130
| +10% | +$823K |
|
243
TJX Companies
TJX
$156B
| $8.74M | ﹤0.01% |
132,048
-83,202
| -39% | -$5.5M |
|
244
British American Tobacco
BTI
$121B
| $8.48M | ﹤0.01% |
218,797
-441
| -0.2% | -$17.1K |
|
245
Veeva Systems
VEEV
$43.9B
| $7.9M | ﹤0.01% |
30,244
+16,220
| +116% | +$4.24M |
|
246
Fortive
FTV
$16B
| $7.7M | ﹤0.01% |
109,062
-157
| -0.1% | -$11.1K |
|
247
American Well
AMWL
$111M
| $6.94M | ﹤0.01% |
19,964
+10,629
| +114% | +$3.69M |
|
248
StoneCo
STNE
$4.34B
| $6.37M | ﹤0.01% |
104,056
-24,456
| -19% | -$1.5M |
|
249
Relay Therapeutics
RLAY
$698M
| $5.92M | ﹤0.01% |
171,286
+91,354
| +114% | +$3.16M |
|
|
KLDO
250
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
| $5.33M | ﹤0.01% |
657,391
+217,391
| +49% | +$1.76M |
|